Company Filing History:
1 out of 140 
1 out of 15,528 
1 out of 78 Years Active: 2017
Title: Damien Habrant: Innovator in Multitarget Inhibitors
Introduction
Damien Habrant is a notable inventor based in Norroy le Veneur, France. He has made significant contributions to the field of pharmacology, particularly in the development of multitarget inhibitors. His work focuses on innovative therapeutic applications that aim to address critical health issues.
Latest Patents
Habrant holds a patent for "Multitarget FAAH and COX inhibitors and therapeutical uses thereof." This patent describes multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1), and/or Cyclooxygenase-2 (COX-2). These inhibitors feature a specific carbamate moiety on the meta or ortho position of the A ring of a substituted biphenyl core, along with a halogen in the ortho position of the B ring. The patent also discusses the therapeutic applications of these inhibitors, particularly in the prevention and treatment of cancer.
Career Highlights
Throughout his career, Damien Habrant has worked with prestigious institutions, including the Fondazione Istituto Italiano Di Tecnologia and the University of California. His research has contributed to advancements in drug development and therapeutic strategies.
Collaborations
Habrant has collaborated with notable colleagues such as Marco De Vivo and Rita Scarpelli. These partnerships have enhanced his research and expanded the impact of his innovations.
Conclusion
Damien Habrant is a distinguished inventor whose work in multitarget inhibitors has the potential to revolutionize cancer treatment. His contributions to pharmacology and collaboration with esteemed institutions highlight his commitment to advancing medical science.